Feider Stephen reported option exercise involving 8,874 derivative units of Beta Bionics, Inc. at $0.00 for $0 on Nov 11, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
8,874Employee Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
29,695Direct
Trade date
Nov 11, 2026Option exercise
Filed
Nov 13, 2026, 4:01 PM ET2-day reporting delay
Accession
0002048588-26-000019Code M · Transaction 400474
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Option exercise8,874$5.10$45,257.40Trade 400472
Nov 11, 2026Sell8,874$17.21−$152,680.72Trade 400473
3 transaction rows in this filing. Joint filers share the same rows.

BBNX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BBNX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +8.2%1w ago +2.7%1d ago +0.1%
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2026. F2: The weighted average sale price for the transaction reported was $17.2054 and the range of prices were between $17.00 and $17.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.